Novo Nordisk sues spas and clinics over off-brand weight loss drugs.

Novo Nordisk has filed lawsuits against certain medical spas, weight loss or wellness clinics, and compounding pharmacies for the unlawful marketing and sales of non-FDA approved counterfeit and compounded semaglutide products claiming to contain semaglutide. The lawsuits follow recent safety warnings from federal regulators amid the rising popularity of semaglutide, the active ingredient in Ozempic and Wegovy, for weight loss. The U.S. FDA has received reports of adverse events after people took injections of semaglutide that came from a compounding pharmacy.